Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Paranasal Sinus Neoplasms 1Papillomavirus Infections 1Neoplasms 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1HIV Infections 1GIST 1Cervical Cancer Screening 1Breast Neoplasms 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Coal Tar × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡